文献速递外周动脉疾病

股总动脉腔内治疗的血管质量倡议研究

Endovascular treatment of the common femoral artery in the Vascular Quality Initiative.
PubMed 文献 · J Vasc Surg · 2016-12-29

基于血管质量倡议(2010-2015)数据,分析1014例股总动脉(CFA)和股深动脉(DFA)腔内治疗(排除急诊和急性肢体缺血)。支架使用与再干预和截肢相关。

要点

  • 1年无截肢生存93.5%,免于通畅丧失或死亡83%,免于再干预生存87.5%。
  • 支架使用与再干预和截肢相关,需长期评估耐久性。

核心结论

  • CFA/DFA腔内治疗围术期并发症和死亡率低,但1年通畅率低于历史CFA内膜剥脱术。

研究设计与样本

  • 回顾性分析血管质量倡议(2010-2015)中1014例CFA/DFA腔内治疗患者,排除急诊和急性肢体缺血。

主要发现

  • 围术期并发症:穿刺点血肿5.2%、动脉夹层2.9%、远端栓塞0.7%、穿刺点狭窄/闭塞0.5%、动脉穿孔0.6%。
  • 1年无截肢生存93.5%,免于通畅丧失或死亡83%,免于再干预生存87.5%(Kaplan-Meier分析)。

关键数值与推荐

  • 死亡的多变量预测因素:组织丢失、COPD、终末期肾病、急诊病例和年龄;阿司匹林使用和非白种人种族为保护因素。
  • 大截肢的预测因素:组织丢失、静息痛、COPD、终末期肾病、支架使用、非行走状态和女性;阿司匹林、P2Y12拮抗剂、他汀使用和初始技术成功为保护因素。
  • 通畅丧失或死亡的预测因素:组织丢失、病例紧急性和非行走状态;再干预的预测因素:组织丢失、COPD、支架使用和既往旁路史。

临床怎么用

  • CFA/DFA腔内治疗可用于合适患者,但需注意支架使用与再干预和截肢相关,应谨慎选择。

局限性

  • 需要更长期分析以更好评估耐久性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Endovascular interventions of the common (CFA) and deep (DFA) femoral arteries are becoming more common. However, there is very little published data for guidance. Our objective was to analyze practice patterns and outcomes from these interventions. METHODS: The Vascular Quality Initiative (2010-2015) was queried for all endovascular interventions of the CFA and DFA. Cases that were emergent or for acute limb ischemia were excluded. Those with isolated CFA with or without DFA treatment were analyzed. RESULTS: There were 1014 patients that had either an isolated CFA intervention (946) with or without a DFA intervention (68). Average age of this isolated cohort was 67.4 ± 10.8 years, and 59% were male. Indications were claudication (67%), rest pain (16.3%), and tissue loss (16.7%). Periprocedural complications were access site hematoma (5.2%), arterial dissection (2.9%), distal embolization (0.7%), access site stenosis/occlusion (0.5%), and arterial perforation (0.6%). Thirty-day mortality was 1.6%. Survival was 92.9% at 1 year and 87.2% at 3 years. Amputation-free survival, freedom from loss of patency or death, and reintervention-free survival were 93.5%, 83%, and 87.5% at 1 year, respectively, by Kaplan-Meier analysis. Multivariable predictors of mortality were tissue loss, chronic obstructive pulmonary disease (COPD), end-stage renal disease, urgent case, and age, whereas aspirin use and non-Caucasian race were protective. Tissue loss, rest pain, COPD, end-stage renal disease, stent use, nonambulatory status, and female sex were predictive of major amputation whereas aspirin use, P2Y12 antagonist use, statin use, and initial technical success were protective. Tissue loss, case urgency and nonambulatory status predicted patency loss or death. Tissue loss, COPD, stent use, and history of prior bypass predicted reintervention. CONCLUSIONS: Endovascular interventions of the CFA/DFA have a low rate of periprocedural morbidity and mortality. One-year patency is lower than historically observed for CFA endarterectomy. Stent use is associated with reinterventions and amputation. Longer-term analysis is needed to better assess durability.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Siracuse JJ, Van Orden K, Kalish JA, et al. Endovascular treatment of the common femoral artery in the Vascular Quality Initiative. J Vasc Surg. 2016. PMID: 28041804. doi:10.1016/j.jvs.2016.10.078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。